We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

22 hedge funds and large institutions have $47.9M invested in Aldeyra Therapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

32% more capital invested

Capital invested by funds: $36.2M → $47.9M (+$11.7M)

12% less funds holding

Funds holding: 25 → 22 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
22
Holders Change
-3
Holders Change %
-12%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
7
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PVI
Pura Vida Investments
New York
+$223K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$159K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$47.4K
4
JP Morgan Chase
JP Morgan Chase
New York
+$7.33K
5
Bank of America
Bank of America
North Carolina
+$4.56K

Top Sellers

1
DM
Deerfield Management
New York
-$1.52M
2
Millennium Management
Millennium Management
New York
-$186K
3
CL
Croft-Leominster
Maryland
-$96K
4
DCM
DAFNA Capital Management
California
-$14K
5
Walleye Trading
Walleye Trading
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$15.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$14.1M – – –
AIC
3
AWM Investment Company
New York
$7.21M – – –
SFM
4
Sphera Funds Management
Israel
$2.89M – – –
BC
5
Boxer Capital
California
$2.29M – – –
BBA
6
Baker Bros. Advisors
New York
$1.11M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.04M +$47.4K +7,761 +6%
KCM
8
Knoll Capital Management
Florida
$1.04M – – –
PVI
9
Pura Vida Investments
New York
$892K +$223K +36,567 +47%
Millennium Management
10
Millennium Management
New York
$782K -$186K -30,497 -23%
WMSA
11
Weiss Multi-Strategy Advisers
New York
$508K -$3.73K -610 -0.9%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$415K +$159K +25,999 +96%
BFA
13
BlackRock Fund Advisors
California
$161K -$318 -52 -0.3%
Northern Trust
14
Northern Trust
Illinois
$100K +$2.93K +480 +4%
FMA
15
FNY Managed Accounts
New York
$39.1K – – –
Morgan Stanley
16
Morgan Stanley
New York
$35K +$3.5K +573 +15%
Bank of America
17
Bank of America
North Carolina
$31K +$4.56K +746 +23%
BA
18
BlackRock Advisors
Delaware
$23K – – –
BIM
19
BlackRock Investment Management
Delaware
$11K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$11K +$7.33K +1,200 +600%
Manulife (Manufacturers Life Insurance)
21
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K – – –
TRCT
22
Tower Research Capital (TRC)
New York
$5K +$3.54K +579 New
DM
23
Deerfield Management
New York
– -$1.52M -267,764 Closed
CL
24
Croft-Leominster
Maryland
– -$96K -17,000 Closed
DCM
25
DAFNA Capital Management
California
– -$14K -2,499 Closed
1
2

ALDX Hedge Fund Activity: Q3 2016 in Review

22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2016, worth a combined $47.9M — up 32% from $36.2M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ALDX and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.

The largest buyer was Pura Vida Investments, adding an estimated $223K. The largest seller was Deerfield Management, exiting entirely with an estimated $1.52M sold.

  • 22 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2016, down from 25 in Q2 2016.
  • Funds reported $47.9M of Aldeyra Therapeutics stock for Q3 2016, up 32% quarter-over-quarter.
  • 1 fund opened new Aldeyra Therapeutics positions in Q3 2016 and 4 closed out, a net change of -3 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2016 was Pura Vida Investments, an estimated $223K added.
  • The largest Aldeyra Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $1.52M sold.

Based on aggregated 13F filings for Q3 2016.